Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials. Issue 3 (17th August 2022)

• Record Type: Journal Article
• Authors: Avihingsanon, Anchalee; Chetchotisakd, Ploenchan; Kiertiburanakul, Sasisopin; Ratanasuwan, Winai; Siripassorn, Krittaecho; Supparatpinyo, Khuanchai; Martin, Hal; Wang, Hui; Wong, TinHung; Wang, Hsiu Yin
• Is Part Of: HIV medicine. Volume 24:Issue 3(2023)
• Page Start: 290
• Page End: 300
• Publication Date: 2022-08-17
• Subjects: Asian -- Bictegravir -- HIV -- regimen switch -- safety -- virologically suppressed; HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.13386
• Languages: English
• ISSNs: 1464-2662

Abstract

Abstract: Objectives: Data on switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed Asian people living with HIV are limited. We performed a pooled analysis of virologically suppressed Asian participants from three international phase III trials to evaluate the efficacy and safety of switching to B/F/TAF. Methods: Virologically suppressed people living with HIV were randomized to switch to B/F/TAF or to stay on baseline regimens. The primary endpoint was the proportion of participants with plasma HIV‐1 RNA ≥50 copies/ml at week 48. We analysed the incidence of adverse events (AEs), laboratory abnormalities, and changes in relevant tolerability parameters through 48 weeks. Results: Overall, 136 Asian participants were included. The proportions of participants with plasma HIV‐1 RNA ≥50 copies/ml at week 48 were low in both arms (0% for B/F/TAF vs 1.4% for those who stayed on baseline regimens). Those who switched to B/F/TAF had virological suppression rates similar to those who stayed on baseline regimens (100% vs 95.9%, p = 0.2485), with no treatment‐emergent resistance. Drug‐related AEs occurred in three participants in each arm; none were serious. No participants discontinued the study drug because of AEs, and no deaths were observed. No significant differences were observed between the arms in the median changes in estimated glomerular filtration rate, body weight, and most lipid parameters. Switching from tenofovir disoproxil fumarate‐containing regimens to B/F/TAF resulted in a significant decrease in tubular proteinuria compared with those who stayed on baseline regimens ( p < 0.01). Conclusions: Virologically suppressed Asian people living with HIV who switched to B/F/TAF maintained 100% virological suppression at week 48, with no treatment‐emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens. Clinical Trial Number: ClinicalTrials.gov (NCT02603120, NCT02652624, and NCT02603107).